U.S. flag

An official website of the United States government

NM_018972.4(GDAP1):c.802_803del (p.Trp268fs) AND Peripheral neuropathy

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Jul 10, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001836931.9

Allele description [Variation Report for NM_018972.4(GDAP1):c.802_803del (p.Trp268fs)]

NM_018972.4(GDAP1):c.802_803del (p.Trp268fs)

Gene:
GDAP1:ganglioside induced differentiation associated protein 1 [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
8q21.11
Genomic location:
Preferred name:
NM_018972.4(GDAP1):c.802_803del (p.Trp268fs)
HGVS:
  • NC_000008.11:g.74364092_74364093del
  • NG_008787.3:g.47963_47964del
  • NM_001040875.4:c.598_599del
  • NM_001362929.2:c.475_476del
  • NM_001362930.2:c.628_629del
  • NM_001362931.2:c.694+1039_694+1040del
  • NM_001362932.2:c.475_476del
  • NM_018972.4:c.802_803delMANE SELECT
  • NP_001035808.1:p.Trp200fs
  • NP_001349858.1:p.Trp159fs
  • NP_001349859.1:p.Trp210fs
  • NP_001349861.1:p.Trp159fs
  • NP_061845.2:p.Trp268fs
  • LRG_244t1:c.802_803del
  • LRG_244:g.47963_47964del
  • NC_000008.10:g.75276327_75276328del
  • NM_018972.2:c.802_803delTG
  • NM_018972.4:c.802_803delTGMANE SELECT
Protein change:
W159fs
Links:
dbSNP: rs765346218
NCBI 1000 Genomes Browser:
rs765346218
Molecular consequence:
  • NM_001040875.4:c.598_599del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_001362929.2:c.475_476del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_001362930.2:c.628_629del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_001362932.2:c.475_476del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_018972.4:c.802_803del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_001362931.2:c.694+1039_694+1040del - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Name:
Peripheral neuropathy
Identifiers:
MONDO: MONDO:0005244; MedGen: C0031117; Human Phenotype Ontology: HP:0009830

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001167076Kariminejad - Najmabadi Pathology & Genetics Center
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Jul 10, 2021)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From Kariminejad - Najmabadi Pathology & Genetics Center, SCV001167076.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 3, 2024